Abstract
Gastric and gastro-esophageal cancers (GC/GEJ) appear as the second cancer-related death worldwide. Diagnosis is made at an advanced stage offering a curative attempt in less than 50% of cases. Despite the improvements of the systemic cytotoxic chemotherapy regimens, the prognosis of patients with metastatic GC/GEJ cancer remains poor. Recent insights in biochemical pathways have permitted to identify potential targets. The extracellular domain of HER2 receptors is implicated in cells’ proliferation and in the anti-apoptotic process occurring in GC/GEJ cancers. Trastuzumab, a monoclonal antibody targeting HER2, in addition to chemotherapy permitted to obtain more than one year of survival in HER2-positive advanced GC/GEJ cancers. Recently, ramucirumab, a humanized monoclonal antibody targeting VEGFR-2 receptor demonstrated its efficacy as a second line treatment for patients with advanced GC/GEJ cancer. These encouraging results have justified evaluating targeted therapies in GC/GEJ cancers. In this review, we summarize targeted therapies that might present clinical efficacy in the treatment of advanced GC/GEJ cancers.
Keywords: Gastric carcinoma, gastric cancer, targeted therapy, anti VEGF, anti EGFR, trastuzumab.
Current Drug Targets
Title:Gastric Carcinoma at the Era of Targeted Therapies
Volume: 17 Issue: 15
Author(s): Johann Dreanic, Marion Dhooge, Elena Sion, Catherine Brezault, Stanislas Chaussade and Romain Coriat
Affiliation:
Keywords: Gastric carcinoma, gastric cancer, targeted therapy, anti VEGF, anti EGFR, trastuzumab.
Abstract: Gastric and gastro-esophageal cancers (GC/GEJ) appear as the second cancer-related death worldwide. Diagnosis is made at an advanced stage offering a curative attempt in less than 50% of cases. Despite the improvements of the systemic cytotoxic chemotherapy regimens, the prognosis of patients with metastatic GC/GEJ cancer remains poor. Recent insights in biochemical pathways have permitted to identify potential targets. The extracellular domain of HER2 receptors is implicated in cells’ proliferation and in the anti-apoptotic process occurring in GC/GEJ cancers. Trastuzumab, a monoclonal antibody targeting HER2, in addition to chemotherapy permitted to obtain more than one year of survival in HER2-positive advanced GC/GEJ cancers. Recently, ramucirumab, a humanized monoclonal antibody targeting VEGFR-2 receptor demonstrated its efficacy as a second line treatment for patients with advanced GC/GEJ cancer. These encouraging results have justified evaluating targeted therapies in GC/GEJ cancers. In this review, we summarize targeted therapies that might present clinical efficacy in the treatment of advanced GC/GEJ cancers.
Export Options
About this article
Cite this article as:
Dreanic Johann, Dhooge Marion, Sion Elena, Brezault Catherine, Chaussade Stanislas and Coriat Romain, Gastric Carcinoma at the Era of Targeted Therapies, Current Drug Targets 2016; 17 (15) . https://dx.doi.org/10.2174/1389450116666150506111327
DOI https://dx.doi.org/10.2174/1389450116666150506111327 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy of Yun Zhi (Coriolus versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis
Recent Patents on Inflammation & Allergy Drug Discovery An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review
Current Drug Delivery Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors
Current Medicinal Chemistry Proteomics Studies in Oncology Towards Personalized Medicine in Public Health: Opportunities and Challenges for OMICS Research in Iran
Current Pharmacogenomics and Personalized Medicine Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Gender Disparity in Pediatric Diseases
Current Molecular Medicine Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Clinical Trials in Chemoprevention of Head and Neck Cancers
Reviews on Recent Clinical Trials HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry